You Do Not Need To Be Selumetinib Hooked To Get Stung

e., death due to disease/progression and TRM combined), the cumulative incidence of death at 3 and 5?years for older HL patients was 23% and 30%, respectively, considering death due to other causes as a competing risk (Fig?2C); this compared http://www.selleck.cn/products/Imatinib(STI571).html with 7% and 10%, respectively, for HL patients aged http://www.selleckchem.com/products/AZD6244.html et?al, 2002), however, the ratio of older patients in HL clinical trials has been lower (i.e., http://www.selleckchem.com/products/SP600125.html (Mir et?al, 1993; Roy et?al, 2000; Engert et?al, 2005). Thus, data describing characteristics and outcomes for older patients with HL have been derived primarily from registry and retrospective population-based series. In these series, older age has been a consistent significant adverse prognostic factor for survival in HL (Guinee et?al, 1991; Erdkamp et?al, 1992; Mir et?al, 1993; Roy et?al, 2000; Stark et?al, 2002; Engert et?al, 2005). The associated chemotherapy regimens in these reports have been heterogeneous, while the last prospective studies of older HL patients that examined ABVD were reported nearly 20?years ago (Mir et?al, 1993; Levis et?al, 1994). Furthermore, to our knowledge, there are no existing data studying Stanford V in older patients with HL. In the randomized trial E2496 that compared ABVD and Stanford V therapy, we identified a high incidence of BLT in older patients treated with ABVD (i.e., 43%), while the tolerability appeared otherwise similar between these regimens. Furthermore, response rates and survival were similar. We found, however, that TRM was significantly increased in older compared with younger HL patients, as was FFS and OS. In interpreting these observations, several factors should be considered.